For Industry

Public Meeting on Functional GI Disorders Patient-Focused Drug Development

On May 11, 2015, FDA conducted a public meeting on Functional GI Disorders Patient-Focused Drug Development. FDA is interested in obtaining patient input on the impact of functional GI disorders on daily life and patients’ views on currently available therapies to treat the functional GI disorders, such as irritable bowel syndrome, gastroparesis, chronic persistent symptomatic gastroesophageal reflux despite standard therapeutic interventions, and chronic idiopathic constipation.


May 11, 2015


1:00 p.m. to 5:00 p.m.


FDA White Oak Campus
10903 New Hampshire Avenue
Building 31, Room 1503 B & C (Great Room)
Silver Spring, MD 20993
Enter at Building 1 to clear security
(Information about arrival to FDA's White Oak campus)


To register for this meeting, visit: Register onlinedisclaimer icon
Registration closed.

Submitting comments to the public docket

In addition to providing input at the public meeting, patient stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on July 13, 2015.


Webcast Recordings

Page Last Updated: 01/08/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English